Article info

Download PDFPDF

890 Nivolumab plus ipilimumab in anti-PD(L)-1 naïve and experienced HCC patients — single institute experience in Taiwan

Authors

Citation

Chiang N, Chen M, Chen S
890 Nivolumab plus ipilimumab in anti-PD(L)-1 naïve and experienced HCC patients — single institute experience in Taiwan

Publication history

  • First published November 2, 2023.
Online issue publication 
November 02, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.